On April 4, PharmaLogic, a portfolio company of Webster Capital and MedEquity Capital, announced that it acquired Agilera Pharma AS. The seller was Insitute for Energy Technology (IFE), a Norwegian company that conducts research on nuclear energy.
Agilera Pharma AS was established as a subsidiary of IFE in 2023. Agilera is a contract development manufacturing organization (CDMO) and a contract research organization. It is based in Norway.
PharmaLogic operates 15 nuclear pharmacies in the northeast and western United States, serving more than 200 hospitals and medical clinics. It is a leading CDMO specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers and other malignancies.
This marks a step forward in PharmaLogic’s strategy to create the first fully-integrated, global CDMO specializing in radiopharmaceutical therapies. Solomon Partners Securities, LLC served as financial advisor on the acquisition. Terms were not disclosed.
According to data in the LevinPro HC database, this transaction represents the 12th CDMO acquisition of 2025. Throughout 2024, there were 28 CDMO transactions reported. If investors continue to announce CDMO transactions at a similar pace that it has been for the rest of 2025, the market will outpace the previous year.
